Abstracts tagged "outcome measures and uric acid"

Abstract Number: 2027 • 2015 ACR/ARHP Annual Meeting
Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout
Sara Bayat¹, Opetaia Aati², Juergen Rech¹, Alexander Cavallaro³, Michael Lell³, Elizabeth Araujo⁴, Christina Petsch⁴, Lisa K. Stamp⁵, Georg A. Schett⁶, Bernhard Manger¹ and Nicola Dalbeth², ¹Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Radiology, University of Erlangen-Nuremberg, Department of Radiology, Erlangen, Germany, ⁴Medical Department 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁶University of Erlangen-Nuremberg, Erlangen, Germany
Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout Background/Purpose: Dual energy computed tomography (DECT) can visualize urate…
Abstract Number: 1814 • 2012 ACR/ARHP Annual Meeting
Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
Michael A. Becker¹, Xiangyang Ye², Kasem S. Akhras³, Rima H. Tawk⁴, Sudhir Unni², Jason Young² and Carl V. Asche⁵, ¹Medicine, University of Chicago, Chicago, IL, ²University of Utah College of Pharmacy, Salt Lake City, UT, ³Global Outcomes Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL, ⁴Center for pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, ⁵Center for Outcomes Research, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Gout is a common acute and potentially progressive disease affecting approximately 8 million Americans. Hyperuricemia (serum urate levels [sUA] >6.8mg/dL) is a major pathogenic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].